Search
Search
Close this search box.

Medical cannabis campaigner Robin Emerson launches own company

Medical cannabis campaigner Robin Emerson has launched his own distribution company, Elite Pharmaco.

Emerson became a high profile advocate for patient access after after his daughter Jorja’s struggle to get treatment for severe epilepsy.

Now he’s going into business with cannabis executive Liam McGreevy to set up his own firm which will bring products to the UK, Ireland and Europe.

Emerson, who credits medical cannabis with saving his daughter’s life, said: “For cannabis to remain a dynamic growth industry, it must offer more products, processes and solutions that are clinically validated, safe, sustainable and cost-effective so more patients can benefit from this transformative plant.

“Our purpose is to meet the needs of the medical cannabis market by providing the best products, expert services and consulting to exceed expectations at all times to suppliers, partners and patients.

Medical cannabis campaigner and Elite Pharmaco founder Robin Emerson.

“This will ensure we have a seamless experience for patients in the UK and in Europe.”

As well as brining existing treatments to market, the company will also launch clinical trials for new drugs to treat a range of conditions.

McGreevy boasts more than a decade’s worth of experience in the industry and is the ‘founder and director of several high-profile cannabis industry businesses’.

McGreevy said: “This is a multifaceted emerging market, characterised by growers at one end to distributors of products at the other.

“As the industry heads towards increased regulation, reaping the benefits of the European medical cannabis market requires a strong and sustainable business strategy sustained by robust and trusted support. At Elite, we bring those qualities and more.”

Elite Pharmaco has already signed a strategic distribution and clinical consulting agreement with MGC Pharmaceuticals, the first cannabis company to list on the London Stock Exchange.

Ron Lipsky of MGC Pharmaceuticals said: “The distributor in every country is crucial to ensuring consistent and effective delivery of the medicines we make to the patients.

“Our choice is always to find distributors with an innate understanding of their local regulations and pathways.

“Given Elite’s personal background and continued commitment to patient access and advocacy, MGC sees the relationship as a significant element of our UK strategy.”

[activecampaign form=31]

🔒 Risk Management Report • Produced in partnership with RELM
Prohibition Partners RELM
📊 New Report Available Now

Relm Risk Briefing: Cannabis 2026

The global cannabis sector has moved from experiment to enterprise. This comprehensive risk briefing examines how regulation, insurance, and operational practices intersect across the international supply chain, drawing on insights from RELM—the only insurer entirely dedicated to the cannabis industry.

What's covered

  • 🌱 Cultivation risk management — biological contamination, environmental instability, and security protocols
  • ⚗️ Manufacturing & extraction — GMP standards, in-house testing, and quality control measures
  • 🔬 Testing & compliance — rigorous protocols ensuring product safety and regulatory adherence
  • 📦 Distribution & logistics — GDP-aligned transport, route monitoring, and cargo insurance
Key focus areas
Cultivation Manufacturing Testing & QC Packaging Distribution Retail & Pharmacy
100% free • Comprehensive risk analysis

Key insights

Industry Maturity Cannabis has evolved from patchwork markets to international enterprise, with risk management now the measure of long-term stability.
Cultivation Challenges Operators addressing biological contamination through controlled-environment agriculture, tissue culture, and IPM protocols.
Quality Control GMP adherence, in-house testing, and selective supplier relationships emerging as critical control points.
Supply Chain Security GDP-aligned transport, route monitoring, and comprehensive insurance remain essential safeguards.
Market Access Initiatives stabilizing domestic supply and expanding pharmacy training improving patient and consumer access.
Produced by Prohibition Partners in collaboration with RELM—the only insurer dedicated to emerging industries like cannabis.
Partnership
Produced by Prohibition Partners in collaboration with RELM

Related Posts

Related Posts

CONNECT

Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you

Categories

Browse by Tags

CATEGORIES

EDITION

BUSINESS OF CANNABIS

© 2023 Prohibition Holdings Ltd. All Rights Reserved.

EDITION

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?